A recent study suggests that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional lifestyle plans.
Published data in a prominent health publication demonstrates that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Users using such drugs must be cognizant of the potential of rapid weight regain when the medication is stopped," warns expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight in about 18 months.
Comparing Approaches
The analysis, which reviewed dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone generally see a slower weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Doctors believe the mode of action of the jabs explains the amplified weight return.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who say that the results "underscore the chronic character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have discontinued the jabs report a sudden return of hunger.
"I experienced a trigger flipping and you're instantly ravenous," said an individual.
The struggle is compounded if individuals have not developed lasting dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates indicate that millions of people in the UK have used these injections in the past year, with demand remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and maintained weight loss relies on ongoing lifestyle changes.
